VPC
TGTX icon

Vestal Point Capital’s TG Therapeutics TGTX Stock Holding History

Vestal Point Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,050,000
Closed -$16M – 76
2024
Q1 		$16M Buy
+1,050,000
New +$16.7M 1.32% 18

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vestal Point Capital's TGTX Position: Q2 2024 in Review

Vestal Point Capital sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 1,050,000 shares — an estimated $16M sold.

Vestal Point Capital first reported a position in TGTX in Q1 2024 and held it in 1 quarter. The position peaked at $16M in Q1 2024. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Vestal Point Capital reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Vestal Point Capital sold 1,050,000 TG Therapeutics shares in Q2 2024, an estimated $16M.
  • Vestal Point Capital first reported a position in TG Therapeutics in Q1 2024 and held it in 1 quarter.
  • Vestal Point Capital's TG Therapeutics position peaked at $16M in Q1 2024.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.